Brokerages Set Qiagen (NYSE:QGEN) PT at $50.88

Qiagen (NYSE:QGEN) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $50.88.

QGEN has been the subject of a number of research analyst reports. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Robert W. Baird increased their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of QGEN. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares during the last quarter. Toronto Dominion Bank bought a new stake in Qiagen in the 2nd quarter valued at $27,000. Massmutual Trust Co. FSB ADV lifted its holdings in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the last quarter. CWM LLC boosted its position in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the period. Finally, Headlands Technologies LLC increased its holdings in shares of Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of QGEN stock opened at $42.78 on Wednesday. The stock has a market cap of $9.76 billion, a PE ratio of 109.69, a price-to-earnings-growth ratio of 3.28 and a beta of 0.41. The stock has a 50-day moving average of $43.43 and a 200-day moving average of $43.73. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a one year low of $39.03 and a one year high of $47.44.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.